WeightControl.com Interview with:
Prof Donal O’ Shea MB, BCh, BAO, MD, FRCPI, FRCP (UK)
UCD School of Medicine
UCD Health Sciences Centre
University College Dublin
WeightControl.com: What is the background for this study?
Response: Glucagon‐like peptide‐1 (GLP‐1) analogs are powerful weight‐loss treatments. These analogs are believed to act primarily by having a major impact on energy intake through delaying gastric emptying and promoting satiety.
We felt this was over simplistic and that it was likely that GLP-1 treatments also had an effect on the other side of the energy balance equation through increasing metabolic activity in fat tissue.